Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.

The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival outcome in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting. In retrospective observational multicenter study, we described the outcome of LGSOC patients enrolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line). Descriptive and survival analyses were performed for each group. Out of 128 patients included in MITO 22, 46 LGSOC patients receiving Bev in first line setting or at the time of first recurrence were identified. In first line, 30 patients received Bev + CT and 65 CT alone and the median PFS were 47.86 months (95% CI: 31.48 - NR) and 22.63 months (95% CI 15–39.24) (p -value 0.0392), respectively. In the recurrent setting, 16 patients who received Bev + CT were compared to 33 women treated with platinum-based CT alone. Median PFS were 37.1 months (95% CI: 13.42–40.56) and 11.22 months (95% CI: 8.26–15.63) (p-value 0.013), respectively. Our study suggests that Bev might be effective in LGSOC both at diagnosis and at the time of relapse. These data warrants further studies. • Bevacizumab shows antitumor activity in LGSC at the time of diagnosis and at the time of first recurrence. • A total of 46 LGSC patients received Bevacizumab in combination with CT and were compared to patients treated with CT alone. • A statistically significant advantage in terms of PFS were reported in the group of patients treated with Bev + CT. [ABSTRACT FROM AUTHOR]